Straumann AGM: shareholders approve all proposals of the Board o

Straumann AGM: shareholders approve all proposals of the Board of Directors

  *Annual Report approved; consent on Compensation Report
  *All Directors re-elected
  *Dividend of CHF 3.75 per share approved (dividend yield: 2.9%)

Basel, 5 April 2013: At Straumann's Annual General Meeting (AGM) in Basel
today, the shareholders approved all the proposals put forward by the Board of
Directors. 490 shareholders attended the meeting and a total of 7 795 121
voting shares were represented, corresponding to 50% of the overall share
capital.

Annual Report approved; consent for Compensation Report

The shareholders approved the 2012 Annual Report, the 2012 Financial
Statements and the discharge of the Board of Directors for their activities in
2012. In an advisory vote, they also consented to the 2012 Compensation
Report. PricewaterhouseCoopers of Basel was reappointed as Statutory Auditors
and Group Auditors for a further term of one year.

Board of Directors re-elected

All the Directors of the Straumann Board - Gilbert Achermann, Dr Sebastian
Burckhardt, Dominik Ellenrieder, Roland Hess, Ulrich Looser, Dr Beat Lüthi,
Stefan Meister and Dr h.c. Thomas Straumann - were re-elected for a further
one-year term of office. The Board convened after the AGM and reappointed
Gilbert Achermann as its Chairman and Thomas Straumann as Vice Chairman.

Stable dividend

The meeting approved the appropriation of the available earnings. CHF 57.9
million were allocated to the 2012 dividend. With CHF 3.75 per share,
Straumann is maintaining the same payout as in previous years, resulting in a
dividend yield of 2.9%. The payout will be made as of 12 April 2013.

2014 AGM

The next ordinary general meeting of Straumann's shareholders will be convened
on 11 April 2014 at the Basel Congress Center.

About Straumann

Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader
in implant, restorative and regenerative dentistry. In collaboration with
leading clinics, research institutes and universities, Straumann researches,
develops and manufactures dental implants, instruments, prosthetics and tissue
regeneration products for use in tooth replacement and restoration solutions
or to prevent tooth loss. Straumann currently employs approximately 2500
people worldwide and its products and services are available in more than 70
countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland

Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01

E-mail: corporate.communication@straumann.com or
investor.relations@straumann.com

Homepage: www.straumann.com

Contacts:

Corporate Communication:

Mark Hill

+41 (0)61 965 13 21

Thomas Konrad

+41 (0)61 965 15 46

Investor Relations:

Fabian Hildbrand

+41 (0)61 965 13 27

Straumann Media Releases subscription:

www.straumann.com/en/home/investor-relations/ir-contacts-and-services/subscription.html

RSS feed subscription:

www.straumann.com/en/home/media/media-releases.news.rss

Upcoming events

30 April 2013 first quarter results (conference call)

20 August 2013 half-year results

31 October 2013 nine months and third-quarter revenue (conference call)

Further information is available on www.straumann.com

# # #

Media release (Download)

Provider                  Channel         Contact
Tensid Ltd., Switzerland  newsbox.ch      Provider/Channel related enquiries
www.tensid.ch             www.newsbox.ch  marco@tensid.ch
                                          +41 41 763 00 50
 
Press spacebar to pause and continue. Press esc to stop.